Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Companyâ€™s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Companyâ€™s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	2.05M 1.8M 1.66M 1.55M 2.91M 193M 2.97M 19.91M 7.7M 95.53M 7.69M 7.53M 331M	P/E 2003 *	-	P/E 2004	-
Enterprise Value	2.05M 1.8M 1.66M 1.55M 2.91M 193M 2.97M 19.91M 7.7M 95.53M 7.69M 7.53M 331M	EV / Sales 2003	-	EV / Sales 2004	-
Free-Float	100%	Yield 2003 *	-	Yield 2004	-

03/10/24	Krystal Biotech, Inc. : Will it go even higher?
31/03/21	NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	CI
11/03/21	Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	CI
05/03/21	Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies	CI
27/02/21	Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	CI
23/02/21	Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology	CI
17/02/21	Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board	CI
10/02/21	Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform	CI
29/01/21	Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer	CI
11/12/20	Oncology Pharma Inc. cancelled the acquisition of acquire 50% stake in Diagnomics, Inc.	CI
06/04/20	Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating Covid-19	CI
20/12/19	Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners	CI
11/12/19	Oncology Pharma Inc. signed a Letter of Intent to acquire 50% stake in Diagnomics, Inc.	CI

12/07/22	Oncology Pharma : Conducting Interviews and Presentations with Investors to Pursue Next Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
29/06/22	Oncology Pharma : Conducting All The Preparations to Take Steps to Forward The Development Process of Nanoemulsion Drug Delivery System	PU
07/06/22	Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022	PU
15/02/22	Oncology Pharma : Financial Statements for the period ended December 31, 2021	PU
15/02/22	Oncology Pharma : Disclosure Statement for the period ended December 31, 2021	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SOURCINGLINK.NET, INC.	-.--%	+9.50%	-	-	2.05M
ELI LILLY AND COMPANY	+7.13%	+9.97%	+55.80%	+163.38%	1,077B
JOHNSON & JOHNSON	+3.99%	+11.50%	+67.09%	+56.27%	613B
ABBVIE INC.	+4.20%	+17.03%	+38.97%	+91.19%	448B
ROCHE HOLDING AG	+0.99%	+4.85%	+28.17%	+22.04%	332B
ASTRAZENECA PLC	+1.82%	+8.19%	+40.04%	+27.45%	293B
NOVARTIS AG	+0.22%	+6.75%	+31.30%	+42.64%	286B
NOVO NORDISK A/S	+0.73%	+8.53%	-27.33%	-40.29%	215B
AMGEN INC.	+1.56%	+6.14%	+29.30%	+61.91%	193B
GILEAD SCIENCES, INC.	+3.26%	+3.33%	+15.55%	+67.87%	159B
Average	+2.39%	+8.48%	+30.99%	+54.72%	401.79B
Weighted average by Cap.	+3.85%	+9.65%	+41.75%	+81.02%

	2003	2004
Net sales	3.28M 2.88M 2.65M 2.48M 4.65M 309M 4.75M 31.86M 12.33M 153M 12.32M 12.05M 530M	1.18M 1.04M 954K 894K 1.68M 111M 1.71M 11.47M 4.44M 55.06M 4.43M 4.34M 191M
Net income	-1.52M -1.33M -1.23M -1.15M -2.16M -143M -2.2M -14.77M -5.71M -70.86M -5.71M -5.58M -246M	-1.56M -1.37M -1.26M -1.18M -2.22M -148M -2.27M -15.2M -5.88M -72.96M -5.88M -5.75M -253M
Net Debt	-1.35M -1.18M -1.09M -1.02M -1.91M -127M -1.95M -13.08M -5.06M -62.75M -5.05M -4.94M -218M	17K 14.91K 13.74K 12.86K 24.12K 1.6M 24.62K 165K 63.9K 793K 63.84K 62.44K 2.75M

SourcingLink.net, Inc. Stock OTC Bulletin Board

Stocks

US8361714053

Pharmaceuticals

Valuation: SourcingLink.net, Inc.

Latest news : SourcingLink.net, Inc.

Press Releases: SourcingLink.net, Inc.

News in other languages: SourcingLink.net, Inc.

Managers and Directors: SourcingLink.net, Inc.

Other Pharmaceuticals

Financials

Company Profile